# A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Study · id `cardio:ct-nct01174160` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01174160](<https://clinicaltrials.gov/study/NCT01174160>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01174160

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

## Technical summary

Registry record NCT01174160. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2015-12-15.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 123 participants (enrolled count; ClinicalTrials.gov record NCT01174160, source copy `cardio:ctgov-nct01174160-2015-12-15`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01174160, source copy `cardio:ctgov-nct01174160-2015-12-15`, retrieved 2026-10-26)
- Primary completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01174160, source copy `cardio:ctgov-nct01174160-2015-12-15`, retrieved 2026-10-26)
- Completion: 2012-10 (actual) (ClinicalTrials.gov record NCT01174160, source copy `cardio:ctgov-nct01174160-2015-12-15`, retrieved 2026-10-26)
- Results first posted: 2015-12-15 (ClinicalTrials.gov record NCT01174160, source copy `cardio:ctgov-nct01174160-2015-12-15`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01174160-2015-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
- Condition: Atrial Fibrillation
- Intervention (Drug): vernakalant hydrochloride
- Intervention (Drug): Placebo to vernakalent hydrochloride
- Lead sponsor: Advanz Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 630e1925857db60f85adf9e53e871d5b4b7ff59863251baae27fbe3b5999f843
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
